[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"facial-aging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:facial-aging":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,54,84,124,156,189,217],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100644275","effect-of-single-facial-acupuncture-on-dermal-structure-and-appearance-satisfaction-100644275",false,"NCT07664280","Effect of Single Facial Acupuncture on Dermal Structure and Appearance Satisfaction","Effects of Single-Session Facial Acupuncture on Dermal Structure and Aesthetic Satisfaction: A Randomized Controlled Trial Combining High-Frequency Ultrasound and Patient-Reported Outcomes","FRA","Inclusion Criteria:\n\n* Adults aged 30 to 60 years old. Individuals concerned about facial aging issues.\n* Individuals without severe chronic diseases.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Individuals with coagulation disorders.\n* Individuals with a keloid constitution or tendency for abnormal scarring.\n* Individuals with acute or chronic facial hemiplegia\u002Fparalysis of any cause.\n* Individuals who have undergone facial cosmetic surgery or cosmetic injections within the past 6 months.\n* Individuals currently taking anticoagulant medications.\n* Individuals with active skin infections.\n* Individuals with a history of severe allergies.\n* Individuals otherwise deemed unsuitable for facial acupuncture by the investigators.",true,"ALL","30 Years","60 Years",{"count":22,"type":23},60,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study aims to investigate the effects of a single session of facial rejuvenation acupuncture on skin structure and personal satisfaction with facial appearance. As facial aging involves complex changes in muscles, skin, and soft tissues, facial acupuncture is considered a potential minimally invasive treatment to help restore balance and promote tissue repair.\n\nResearchers will enroll 60 healthy adults aged 30 to 60 who are concerned about facial aging. Participants will be randomly assigned to either an immediate intervention group or a waitlist control group. The intervention group will receive one session of facial acupuncture at the start of the study. The control group will continue their normal daily skincare routine for 6 weeks, after which they will receive the same single acupuncture treatment.\n\nAll participants will be monitored weekly for 6 weeks. The research team will use non-invasive tools, including high-frequency skin ultrasound, 3D facial scanning, and a digital complexion analysis system, to objectively measure changes in skin thickness, facial volume, and wrinkles. Participants will also complete questionnaires at various time points to share their satisfaction with their appearance, self-confidence, and quality of life.",[29,30,31],"Facial Aging","Wrinkles","Skin Aging",[33,34,35,36,37,38,39,40],"Facial Rejuvenation Acupuncture","Acupuncture Therapy","Dermal Thickness","Skin Rejuvenation","High-Frequency Ultrasound","3D Facial Scanning","Facial Contouring","Patient Satisfaction","RECRUITING","2026-06-17",{"date":44,"type":45},"2026-06-24","ACTUAL",{"date":47,"type":45},"2026-06-11",{"date":49,"type":23},"2027-08-31",{"name":51,"class":52},"Far Eastern Memorial Hospital","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":18,"minAge":61,"maxAge":20,"enrollmentInfo":62,"targetDuration":4,"studyType":24,"phases":64,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100642033","phase-4-botulinum-toxin-type-a-injection-sites-for-oral-commissure-ptosis-100642033","NCT07646886","Botulinum Toxin Type A Injection Sites for Oral Commissure Ptosis","Injection Site-Based Multicenter Randomized Controlled Trial: Efficacy and Safety of Focal Botulinum Toxin Type A Injection for Oral Commissure Ptosis","Inclusion Criteria:\n\n* Aged 18 to 60 years, any gender\n* Meet the diagnostic criteria for oral commissure ptosis: bilateral oral commissure ptosis angle (angle between the oral commissure point and the horizontal line of the ipsilateral vermilion border) \\> 1° at rest\n* Have clear aesthetic demand for oral commissure ptosis improvement and can complete full-cycle follow-up\n* No redness, swelling, ulcer, scar, deformity or active infection in the perioral and mental regions\n* Have not participated in other interventional clinical trials within 3 months before enrollment\n\nExclusion Criteria:\n\n* Hypersensitivity to botulinum toxin type A, lidocaine or excipients of injection preparations; or contraindications to botulinum toxin injection (myasthenia gravis, Lambert-Eaton syndrome, motor neuron disease, severe liver and kidney dysfunction, coagulation disorders, uncontrolled autoimmune diseases, malignant tumors)\n* History of mid-lower facial botulinum toxin type A injection, soft tissue filling, laser\u002Fradiofrequency rejuvenation, perioral surgery or orthognathic treatment within 6 months before enrollment\n* Planned perioral treatment within 6 months after enrollment that may affect efficacy evaluation\n* Pregnant or lactating women, or those planning to become pregnant within 6 months\n* Acquired oral commissure ptosis caused by facial nerve palsy\u002Fsequelae, perioral scar traction, severe jaw deformity or severe alveolar bone resorption\n* Severe facial asymmetry (difference in bilateral oral commissure ptosis angle \\> 2°)\n* History of botulinum toxin allergy or severe adverse reactions after previous botulinum toxin injection\n* Currently using aminoglycoside antibiotics, quinine, calcium channel blockers, anticoagulants or other drugs that may affect botulinum toxin efficacy or increase bleeding risk and cannot discontinue\n* History of mental illness, drug\u002Falcohol abuse, or poor compliance unable to complete follow-up\n* Other conditions deemed unsuitable for enrollment by the investigator","18 Years",{"count":63,"type":23},266,[65],"PHASE4","This multicenter, prospective, randomized parallel-controlled, assessor-blinded clinical trial aims to address the core clinical pain point of lack of high-level evidence and non-standardized operation in injection site selection for BTX-A treatment of oral commissure ptosis. A total of 266 eligible subjects will be randomly assigned in a 1:1 ratio to receive either upper DAO or lower DAO BTX-A injection. The study will compare the clinical efficacy, time-effect characteristics and safety profiles of the two regimens, and conduct stratified analysis of treatment response in different patient subtypes. The results will determine the optimal injection site for Chinese population, establish standardized operation specifications, fill the international evidence gap, and provide level I evidence for clinical practice.",[29,68,69],"Melomental Folds","Oral Commissure Ptosis",[71,69,68,72,73,74],"Botulinum Toxin Type A","Depressor Anguli Oris Muscle","Randomized Controlled Trial","Injection Site","NOT_YET_RECRUITING",{"date":77,"type":45},"2026-06-15",{"date":79,"type":23},"2026-07-01",{"date":81,"type":23},"2027-12-01",{"name":83,"class":52},"Peking University",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":24,"phases":94,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":53},"100610461","early-phase-1-secretome-treatment-for-facial-rejuvenation-100610461","NCT07227883","Secretome Treatment for Facial Rejuvenation","Blinded, Randomized, Controlled, Trial to Evaluate the Efficacy and Safety of Autologous Hair Follicle Secretome for Facial Rejuvenation","Inclusion Criteria\n\n* Male or Female\n* Age: ≥30 and ≤ 75 at the time of consent.\n* Fitzpatrick skin types I-V\n* Moderate to very severe facial aging according to the SASSQ for the categories of elasticity, wrinkles, and skin roughness.\n* Willing to refrain from cosmetic procedures throughout the study period (i.e. laser treatments, chemical peels, microneedling, dermal filler injections, neuromodulator injections, etc.)\n* Willing to use study support products as directed and will not introduce any new skin care or makeup products throughout the study period. Subjects will be provided with a Skincare Kit: Cetaphil Gentle Skin Cleanser 20 oz, Cetaphil Daily Hydrating Lotion 3 oz, Cetaphil Sheer Mineral Liquid Face Sunscreen SPF 50 . Two of each will be provided with application instructions.\n* Male subjects with facial hair must be willing to shave the morning of their treatments\u002Ffollow-up visits.\n* Willing to minimize sun\u002Fultraviolet light exposure for the duration of the study, including all of the following: applying sunscreen daily, at least 15 minutes before going outside; wearing sun-protective clothing (e.g., a hat, sunglasses) when outdoors; reapplying sunscreen every 2 hours during outdoor activities; avoiding tanning bed\u002Ftanning product use.\n* Competent and willing to provide written, informed consent to participate in all study activities\n* Willing and able to tolerate multiple injections and attend all study visits\n* Negative urine pregnancy test result at the time of screening (if applicable)\n* For female subjects of childbearing potential, must be willing to use an acceptable form of birth control (oral contraceptives, hormonal implants, intrauterine device \\[IUD\\], hormonal injectables specifically for birth control, contraceptive patch or ring, tubal ligation \\[tubes tied\\], or total sexual abstinence) during the entire course of the study. All systemic birth control measures (oral, hormonal implants, injectables) must be in consistent use for at least 30 days prior to study enrollment. A female is considered of childbearing potential unless she is postmenopausal, without a uterus and\u002For both ovaries, or has had a bilateral tubal ligation.\n\nExclusion Criteria\n\n* Use of topical tretinoin, adapalene, tazarotene, hydroquinone, imiquimod, 5-fluorouracil, ingenol mebutate, concentrated hydrogen peroxide, diclofenac, vitamin C, alpha hydroxy acids, or photodynamic therapy (PDT) to the face within 4 weeks prior to baseline photography and throughout the study period\n* Dermatologic diseases or conditions (e.g. atopic dermatitis, psoriasis, rosacea, seborrheic dermatitis, wounds, infections, irritation, sunburn, windburn, etc.) in the treatment area that could interfere with the study, in the opinion of the Investigator\n* Starting use or stopping use of GLP-1 agonists, or planned weight loss or gain during the study period. Subjects using GLP-1 agonists must be taking the drug for maintenance AND body weight must have been stable for at least 3 months prior to initial study treatment.\n* History of keloid formation, hypertrophic scarring, or abnormal\u002Fdelayed wound healing\n* Previous medical aesthetic rejuvenation treatments on the face, such as chemical peel, dermabrasion, non-ablative or ablative resurfacing procedure, or face-lift with laser or other devices, up to 3 months prior to baseline photography\n* Treatment with neuromodulators in crow's feet, glabellar region, or frontalis muscles within 4 months prior to baseline photography\n* Treatment with dermal fillers, collagen stimulators, fat injections or permanent fillers within the past 6 months prior to baseline photography.\n* Patients using other anti-aging treatments\u002Fprocedures\u002Fsystemic medications or injections administered\u002Fprescribed by a medical professional before starting the study, if the investigator believes they will confound the results. Consulting with Sponsor is encouraged.\n* Heavy smoker (\\>1 pack of cigarettes a day)\n* Energy-based device (i.e., radiofrequency device treatments, microfocused ultrasound device or other ultrasound-based device treatments, laser and light-based device treatments, microneedling) treatment in the treatment area within 6 months prior to baseline photography\n* Currently be taking isotretinoin (Accutane).\n* Subjects on an immunosuppressant or have an autoimmune condition (except stable, controlled Hashimoto's thyroiditis)\n* Surgery (i.e., face lift, eyebrow lift, neck lift or lower rhytidectomy, liposuction, etc.) during the 12-month period prior to baseline photography\n* Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study\n* Severe active infection (e.g. HIV, HepB or C, UTI, etc.)\n* Current or recent (within last 5 years) malignancy (except basal cell and squamous cell skin cancers as long as basal cell was not on the face)\n* History of systemic chemotherapy or radiation within the last 5 years\n* Continuous\u002Fdaily use of nonsteroidal anti-inflammatory or Vitamin E, unless discontinued within 7 days before 1st treatment and only used as needed through the trial period.\n* Anticipated pregnancy or trying to become pregnant in the next year\n* Current anticoagulant therapy (heparins; factor Xa inhibitors; direct agents such dabigatran, rivaroxaban, apixaban, endoxaban and betrixaban; warfarin\u002Fcoumarins). Low dose aspirin and omega-3 supplements allowed.\n* Any other criterion that is based on the clinical judgment of the investigator may place the subject at risk or confound study results","70 Years",{"count":93,"type":23},24,[95],"EARLY_PHASE1","Secretome treatment for facial rejuvenation",[29,98,99,100],"Rejuvenation","Stem Cell","Stem Cell Banking",[102,103,104,105,106,107,108,109,110,111,112,113],"stem cells","secretome","autologous","hair follicle","aging","facial","face","under eyes","wrinkles","anti-aging","rejuvenation","regeneration","2026-04-30",{"date":116,"type":45},"2026-05-04",{"date":118,"type":45},"2025-12-15",{"date":120,"type":23},"2026-12-20",{"name":122,"class":123},"Acorn Biolabs Inc.","INDUSTRY",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":17,"sex":18,"minAge":61,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":24,"phases":134,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100628846","phase-3-objective-evaluation-of-intradermal-msc-derived-exosome-therapy-on-facial-skin-quality-100628846","NCT07466953","Objective Evaluation of Intradermal MSC-Derived Exosome Therapy on Facial Skin Quality","Objective Analysis of the Effects of Intradermally Administered Mesenchymal Stem Cell-Derived Suspended Exosome Therapy on Facial Skin Quality Using a Standardized Imaging System","Inclusion Criteria:\n\n* • Adults aged 18 to 65 years\n\n  * Individuals presenting facial skin aging signs\n  * Willingness to undergo three intradermal treatment sessions\n  * Ability to comply with study visits and follow-up assessments\n  * Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n\n  * Active skin infection, inflammatory skin disease, or open wounds in the treatment area\n  * History of allergic reactions to injectable dermatologic treatments\n  * Use of systemic or topical retinoids within the past 6 months\n  * Receipt of facial cosmetic procedures (laser treatment, fillers, botulinum toxin, PRP, or similar treatments) within the past 6 months\n  * Presence of autoimmune disease or immunosuppressive conditions\n  * Active malignancy or ongoing cancer treatment\n  * Participation in another clinical study within the past 3 months","65 Years",{"count":133,"type":23},30,[135],"PHASE3","This study aims to evaluate the potential effects of mesenchymal stem cell-derived suspended exosome therapy on facial skin quality using objective imaging analysis. Thirty adult participants will receive intradermal exosome applications in three treatment sessions performed at one-month intervals. Facial skin analysis will be conducted using the VISIA imaging system before each treatment session and six months after the final treatment. The study will examine changes in multiple facial skin characteristics including wrinkles, pigmentation, skin texture, pores, UV spots, red areas, brown spots, and porphyrins to determine whether exosome therapy may improve overall facial skin quality.",[31,29,138],"Skin Quality",[140,141,142,143,144,145,146],"Exosome Therapy","Mesenchymal Stem Cell Exosomes","Facial Rejuvenation","Skin Imaging","VISIA Skin Analysis","Skin Aging Treatment","Regenerative Dermatology","2026-03-08",{"date":149,"type":45},"2026-03-12",{"date":151,"type":23},"2026-04-01",{"date":153,"type":23},"2026-12-31",{"name":155,"class":52},"Mert Ersan",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":131,"enrollmentInfo":164,"targetDuration":4,"studyType":24,"phases":165,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":53},"100606635","bridging-technique-validation-for-nasolabial-folds-jn-bridge-1-100606635","NCT07178119","Bridging Technique Validation for Nasolabial Folds JN-BRIDGE-1","A Prospective Clinical Evaluation of the Bridging Technique Using AILEENE Vol. 2 Dermal Filler for the Treatment of Nasolabial Folds","BRIDGING","Inclusion Criteria\n\nAdults aged 30 to 65 years, inclusive, at the time of screening.\n\nMale or female, able and willing to comply with study procedures.\n\nPresence of visible bilateral nasolabial folds (NLF), each with a score of 2 or higher on the Nasolabial Fold Severity Scale (NLFSS), as assessed by the Principal Investigator.\n\nWilling to undergo facial dermal filler treatment using the Bridging Technique with AILEENE Vol. 2.\n\nIn generally good health, without uncontrolled chronic illness or active skin disease that could interfere with treatment or healing.\n\nAble to provide written informed consent and understand the nature and purpose of the study.\n\nWilling to refrain from undergoing any other facial cosmetic procedures (e.g., dermal fillers, botulinum toxin, laser, surgery, or radiofrequency) during the six-month study period.\n\nAgree to photographic documentation of the treatment area and follow-up assessments, and willing to allow use of anonymized photographs for blinded evaluation and publication.\n\nFor women of childbearing potential: negative urine pregnancy test at baseline.\n\nFemale participants of childbearing potential will undergo a urine pregnancy test on the day of treatment as a safety precaution, since there is insufficient evidence on filler safety during pregnancy.\n\nExclusion Criteria Presence of NLF graded less than 2 on the NLFSS on either side of the face.\n\nKnown allergy or hypersensitivity to hyaluronic acid (HA), lidocaine, or any component of AILEENE Vol. 2.\n\nHistory of severe allergic reactions, anaphylaxis, or allergy to local anesthetics.\n\nPrior use of dermal fillers, permanent implants, or other cosmetic procedures in the NLF area or lower face within the past 12 months.\n\nUse of botulinum toxin, chemical peels, laser, radiofrequency, or cryotherapy in the mid- or lower face within the last six months.\n\nActive skin infection, inflammation, herpes simplex (cold sore), acne, or other dermatologic condition in the treatment area.\n\nUse of topical medications such as retinoids or corticosteroids on the face within 30 days prior to treatment.\n\nCurrent or recent use (within 14 days) of anticoagulant, antiplatelet, or non-steroidal anti-inflammatory drugs (NSAIDs) that may increase the risk of bruising or bleeding.\n\nHistory of bleeding disorders.",{"count":22,"type":23},[26],"The goal of this clinical study is to learn whether the Bridging Technique can safely and effectively treat nasolabial folds (NLF, also known as smile lines) in adults. The main questions are:\n\nDoes the Bridging Technique, which places very small amounts of filler in thin horizontal threads (less than 0.05 milliliters \\[ml\\] per retrograde placement), improve the appearance of nasolabial folds?\n\nIs the treatment safe, and are participants satisfied with the results?\n\nThe Bridging Technique is a new method of filler injection where very small amounts of hyaluronic acid (HA) filler are placed in thin horizontal lines under the fold using a blunt cannula. These small \"bridges\" of filler act like internal support, helping to lift and soften the fold without overfilling or distorting the natural shape of the face.\n\nParticipants will:\n\nReceive an HA dermal filler (AILEENE Vol. 2) injected with the Bridging Technique to both nasolabial folds.\n\nAttend follow-up visits at Week 2 (virtual safety check), Week 4, Month 3, and Month 6.\n\nHave photographs taken at baseline, Week 4, Month 3, and Month 6, which will be reviewed by independent observers who are blinded to the visit sequence.\n\nComplete short questionnaires about their satisfaction and experience.\n\nThe study includes 60 adults aged 30 to 65 years. Each participant may receive up to 1.0 ml of filler in total across both folds. An optional top-up treatment may be offered at Week 2 or Week 4 if clinically indicated, using only the remaining balance of the total 1.0 ml allowance. Any top-up will be performed with a new, sterile syringe, not with filler physically left over from the first visit. There is no cost to participants, and participation is voluntary.",[168,29,36,169],"Nasolabial Fold Correction","Wrinkles Such as Nasolabial Folds",[171,172,173,174,175,176,177,178,179],"Hyaluronic Acid Filler","Dermal Filler","AILEENE Vol. 2","Bridging Technique","Minimally Invasive Aesthetics","Non-Surgical Facial Rejuvenation","Wrinkle Correction","Global Aesthetic Improvement Scale (GAIS)","Nasolabial Fold Severity Scale (NLFSS)","2025-12-03",{"date":182,"type":45},"2025-12-04",{"date":184,"type":45},"2025-11-22",{"date":186,"type":23},"2026-11",{"name":188,"class":52},"Dr. Joseph M Novoa Libermann",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":17,"sex":18,"minAge":61,"maxAge":131,"enrollmentInfo":196,"targetDuration":4,"studyType":24,"phases":198,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":4},"100588948","restructuring-the-mandibular-angle-in-facial-aging-a-novel-tecnique-using-poly-l-lactic-acid-100588948","NCT06948045","RESTRUCTURING THE MANDIBULAR ANGLE IN FACIAL AGING: A NOVEL TECNIQUE USING POLY-L-LACTIC ACID","Restructuring the Mandibular Angle in Facial Aging: a Novel Tecnique Using Poly-L-Lactic Acid","Inclusion Criteria:\n\n1. Male or female individuals aged between 18 and 65 years of age.\n2. Immunocompetent individuals.\n3. Medical history and physical examination that, in the opinion of the investigator, do not prevent or contraindicate participation in the study or the use of the investigational product.\n4. Female research participants of childbearing potential with a negative UPT at baseline (Day 1). These participants must use a highly effective contraceptive method throughout the study: combined oral contraceptives (estrogen and progesterone) or implanted\u002Finjectable contraceptives (with a stable dose for at least 1 month prior to study entry), bilateral tubal ligation, hormonal intrauterine device (inserted at least 1 month before entering the study), strict abstinence (at least 1 month prior to study entry and agreeing to continue throughout the study duration), vasectomized partner (at least 3 months before study entry), or condom use.\n5. Women not of childbearing potential (e.g. postmenopausal with no menstrual bleeding for 1 year prior to study entry, hysterectomy, or bilateral oophorectomy).\n6. Research participants who are willing and able to comply with the duration and procedures required by the study protocol.\n7. Research participants who understand and sign the ICF and the ICF for image use authorization upon entering the study, before any investigational procedures are performed.\n\nExclusion Criteria:\n\n1. Participants unable to understand the research protocol and\u002For follow the study schedule.\n2. Pregnant or breastfeeding women, or those planning to become pregnant during the study period.\n3. History of treatment in the past 6 months or planning to undergo procedures with lasers, intense pulsed light, radiofrequency, microfocused ultrasound, or deep chemical peels.\n4. History of treatment with botulinum toxin on the face in the past 6 months or planning to undergo this procedure.\n5. History of treatment with hyaluronic acid-based or other non-permanent dermal fillers on the face in the past 12 months, or planning to undergo this procedure.\n6. History of treatment with collagen biostimulators on the face, such as poly-L-lactic acid (PLLA), calcium hydroxyapatite, or polycaprolactone, in the past 36 months, or planning to undergo this procedure.\n7. History of treatment with or planning to use permanent fillers on the face.\n8. Current use, use within the past 3 months, or planned use of collagen-based supplements.\n9. Any surgical procedure or other treatment previously performed that has affected the area to be assessed in this study.\n10. Active inflammation or infections in the facial region.\n11. Severe psychiatric disorders.\n12. Any other uncontrolled, chronic, or severe medical condition that, in the investigator's opinion, may interfere with the interpretation of the clinical study results or pose significant risk to the research participant.\n13. History of sensitivity to any component of the product used in the study.\n14. Vulnerable participants (such as those deprived of liberty), as defined in Section 1.61 of the International Conference on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).\n15. History of poor treatment adherence or demonstrated lack of cooperation in adhering to the study protocol.\n16. Current participation in any other drug or device clinical study OR participation within 30 days prior to Day 1 or within an exclusion period of a previous clinical study.",{"count":197,"type":23},46,[26],"Skin laxity is a common complaint among patients seeking aesthetic dermatological interventions, affecting the facial contour, especially in the mandibular angle, due to bone aging and the loss of tissue support in the lower third of the face. Facelift surgery is an effective method to address this issue, but it is invasive and may impact the definition of the jawline. As an alternative, poly-L-lactic acid (PLLA) stimulates collagen production, improving facial contour in a minimally invasive manner. This study aims to evaluate the safety and effectiveness of a new, low-cost, and quick application technique using poly-L-lactic acid in the mandibular angle and anterior to the mandibular ligament. The proposed technique seeks to enhance facial contour, provide an additional lifting effect, and contribute to overall facial rejuvenation. This is a clinical, prospective, and interventional study, allowing the analysis of clinical outcomes in terms of efficacy and safety. Twenty volunteers aged between 18 and 65, of both genders, with no restrictions on the use of collagen bio-stimulators, will be recruited. After confirming inclusion and exclusion criteria, participants will sign the Informed Consent Form (ICF) and be eligible for the study. The first intervention will occur at visit 2 (day 1), the second intervention at visit 3 (day 30 ± 15), and the third intervention will be performed as indicated at visit 4 (day 60 ± 15). Final follow-up will take place at visit 5 (day 90 ± 15). Questionnaires will be applied and photographs taken at all visits. Injections will be administered with poly-L-lactic acid in the mandibular angle region and anterior to the mandibular ligament. The study will be funded by the Research Department of the Hexsel Dermatology Clinic, and the data collected will be used to prepare an article for publication.",[201,29],"Skin Laxity",[203,204,205,206,207],"Restructuring the mandibular angle in facial aging: a new technique using poly-L-lactic acid (PLLA)","PLLA","poly-L-lactic acid","mandibular angle","facial aging","2025-11-21",{"date":210,"type":45},"2025-11-26",{"date":212,"type":23},"2026-02-01",{"date":214,"type":23},"2027-02",{"name":216,"class":52},"Doris Hexsel",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":17,"sex":18,"minAge":223,"maxAge":20,"enrollmentInfo":224,"targetDuration":226,"studyType":227,"phases":4,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":53},"100587183","quantified-evaluation-of-noninvasive-system-delivering-microwave-energy-for-unwanted-fat-reduction-and-skin-tightening-in-asians-100587183","NCT06925074","Quantified Evaluation of Noninvasive System Delivering Microwave Energy for Unwanted Fat Reduction and Skin Tightening in Asians.","Inclusion Criteria:\n\n* Men and women aged between 20 and 60.\n* Subjects who are capable of understanding and comply with the study procedures, instructions, and visit schedule.\n* Subjects who voluntarily decide to participate in the entire course of the trial and provide written consent in the Informed Consent Form.\n\nExclusion Criteria:\n\n* Subjects with autoimmune diseases\u002Freceived immunotherapy and subjects with diabetes mellitus.\n* Subjects with a history of a hypertrophic scar.\n* Pregnant or breastfeeding women.\n* Subjects with untreated epilepsy or underlying porphyria.\n* When there is an active disease (such as inflammation, infection or tumors) in or near the intended treatment site.\n* Treatment procedure (e.g., bioresorbable fillers, laser\u002Flight therapies, botulinum toxin A injections, facial lift, facial peels, excisional facial surgery, dermal photorejuvenation, oral or maxillofacial surgery, etc.) that may interfere with the treatment area or evaluation within 6 months before screening as determined by the Principal Investigator.\n* The subject who received soft tissue augmentation at the treatment site at any time before screening as determined by the Principal Investigator.\n* Subjects with a scar or skin lesion at the treatment site that may interfere with the judgment of the treatment effect.\n* Subjects who participated in another clinical trial within 60 days before screening or plan to participate in another investigation during this study.\n* Subjects who plan to receive other wrinkle improvement treatments in the face during this trial.\n* Subjects who are otherwise determined by the investigator as ineligible for this study.","20 Years",{"count":225,"type":23},15,"3 Months","OBSERVATIONAL","The goal of this observational study is to evaluate the effectiveness and safety of microwave-assisted heating technology in facial fat reduction and skin tightening in Asians.\n\nThe main questions it aims to answer are:\n\n1. How effective is the microwave-based system in reducing fat and tightening Skin?\n2. What objective methods can be used to measure treatment outcomes?\n3. What are the optimal treatment parameters for maximum efficacy?\n4. What are the safety and side effects associated with the treatment?\n5. How long-lasting are the results?\n\nParticipants will go through three treatment sessions using the \"DEKA\" ONDA Microwave treatment system, with each session lasting 12 minutes.",[29,201,230],"Cheek Wrinkles",[232,233,234,235,236],"3D imaging","Skin laxity","Microwaves","Fat reduction","Facial aging","2025-04-06",{"date":239,"type":45},"2025-04-13",{"date":241,"type":23},"2025-05",{"date":243,"type":23},"2026-04",{"name":245,"class":52},"Chang Chang Cheng"]